Advanced Enzyme Technologies Ltd (NSE:ADVENZYMES)
₹ 324.35 -5.45 (-1.65%) Market Cap: 36.32 Bil Enterprise Value: 30.08 Bil PE Ratio: 21.52 PB Ratio: 2.22 GF Score: 89/100

Q1 2025 Advanced Enzyme Technologies Ltd Earnings Call Transcript

Aug 13, 2024 / 10:30AM GMT
Release Date Price: ₹416.65 (+3.16%)

Key Points

Positve
  • Revenue increased by 5% year-on-year to INR1,545 million.
  • EBITDA grew by 16% year-on-year to INR512 million.
  • Profit after tax increased by 19% year-on-year to INR350 million.
  • The company anticipates robust growth in all segments in the second half of the year.
  • R&D spending increased, indicating a focus on innovation and future growth.
Negative
  • EBITDA declined by 8% on a sequential basis.
  • Human Nutrition segment remained largely unchanged, contributing 65% to revenue.
  • Animal Nutrition business declined by 7% on a sequential basis.
  • Bio processing segment de-grew by 3% on a sequential basis.
  • The largest product, anti-inflammatory enzyme, saw a 20% decline in sales year-on-year.
Operator

Ladies and gentlemen, good day, and welcome to Advanced Enzyme Technologies Limited Q1 FY25 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Ronak Saraf, Investor Relations. Thank you, and over to you, sir.

Ronak Saraf
Advanced Enzyme Technologies Ltd - Investor Relations Manager

Good evening, everyone. Welcome to Advanced Enzymes Q1 FY25 earnings conference call. I'm Ronak Saraf, the Manager of Investor Relations here at Advanced Enzymes. We hope you all have gone through our financials, press release and the presentation, which has been posted in our Investor Relations section on our website.

We have with us Mr. Mukund Kabra, Whole-Time Director; Mr. Beni Rauka, Group CFO. Today, the management will discuss the performance and business highlights, update on strategies and respond to any questions that you may have. As is usual, for ease of discussion, we will look at the consolidated financials.

Before we proceed, I would like to draw your

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot